Close Menu

NEW YORK — Seventh Sense Biosystems announced today that it has signed a distribution and equity investment deal with Japanese commercial clinical lab Miraca.

Medford, Massachusetts-based Seventh Sense markets a one-step, push-button device called Tap that uses a microneedle array to collect capillary blood from the arm. It was cleared by the US Food and Drug Administration in 2017 and was CE marked last year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.